AAD 2026Abstract 71092
Sustained effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis overall and in high-impact areas
2-year results from the POSITIVE study
Augustin M, Sommer R, Gerdes S, Weger W, Laws P, Ghislain PD, Mburu S, Koscielny V, Massana E, Kasujee I, Mrowietz U
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Psoriasis
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.1680 · Not in PubMed: details from Crossref